Protagonist Therapeutics Inc
Protagonist Therapeutics Inc (PTGX) Straddle
PTGX straddle scan found 54 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 54.5%.
Read more
Trading a PTGX straddle lets you take a pure volatility position on Protagonist Therapeutics Inc without committing to a direction. Protagonist Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate PTGX straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on PTGX profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Protagonist Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the PTGX straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the PTGX straddle is the cleanest expression of that view. Our scanner prices every PTGX straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a PTGX straddle into a catalyst or short a PTGX straddle to harvest decay, the options straddle setups that matter are all in one place.
| Apr 16, 2027 | 210.00 | $68.03 | 206 | 34% | 54.5% | $278.03 | $141.98 | 0 |
| Apr 16, 2027 | 220.00 | $77.18 | 206 | 34% | 54.3% | $297.18 | $142.83 | 0 |
| Apr 16, 2027 | 190.00 | $52.85 | 206 | 34% | 53.8% | $242.85 | $137.15 | 0 |
| Apr 16, 2027 | 200.00 | $60.55 | 206 | 34% | 53.8% | $260.55 | $139.45 | 0 |
| Apr 16, 2027 | 195.00 | $56.68 | 206 | 34% | 53.7% | $251.68 | $138.33 | 0 |
| Jan 15, 2027 | 185.00 | $43.20 | 115 | 34% | 53.4% | $228.20 | $141.80 | 0 |
| Apr 16, 2027 | 180.00 | $46.55 | 206 | 34% | 53.4% | $226.55 | $133.45 | 0 |
| Apr 16, 2027 | 185.00 | $49.85 | 206 | 34% | 53.4% | $234.85 | $135.15 | 0 |
| Apr 16, 2027 | 175.00 | $44.05 | 206 | 34% | 52.9% | $219.05 | $130.95 | 0 |
| Jan 15, 2027 | 165.00 | $30.75 | 115 | 34% | 52.7% | $195.75 | $134.25 | 0 |
As of September 23, 2026
Find the right straddle before volatility moves
Track PTGX straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→